JAMA Oncol: For hormone receptor-positive breast cancer, Pabocinil ➕Letrozole is better than Pabocinib ➕Fulvestrant

Breast cancer is the number one killer of women

Breast cancer is the number one killer of women

The top ten cancer types with the number of new cancer cases in 2020 The top ten cancer types with the number of new cancer cases in 2020

With advances in medicine , pharmaceutical hormone receptor-positive breast cancer is also increasing

With advances in medicine , pharmaceutical hormone receptor-positive breast cancer is also increasing

It is a kind of medicine for the treatment of advanced breast cancer

After Pabosini was listed in China, it was changed to Aiboxin

In the clinic, and Paboxini Letrozole, fulvestrant combination therapy is superior to letrozole or fulvestrant individual therapeutic effect

Fulvestrant combination therapy is superior to fulvestrant individual therapeutic effect

Compared with letrozole-pabocinib, JAMA fulvestrant-pabocinil did not improve in terms of progression-free survival, confirming that letrozole is the preferred pabocinib partner in this patient group

In this international, randomized, open-label, phase 2 clinical study conducted from July 30, 2015 to January 8, 2018, subjects were hormone receptor positive, ERBB2 negative, and had not received previous treatment Of patients with advanced breast cancer

In this international, randomized, open-label, phase 2 clinical study conducted between July 30, 2015 and January 8, 2018, the subjects were hormone receptor positive, ERBB2 ERBB2 negative, and had not previously received Treatment of advanced breast cancer patients

Patients were randomly assigned (1:1 ratio) to receivefulvestrant or letrozole

The results found that , fulvestrant - Median group of researchers Paboxini assessment of progression-free survival was 27.

Further , fulvestrant - and letrozole objective response rate (46.

Although fulvestrant-palbociclib showed significant anti-tumor activity, this randomized clinical trial failed to determine whether the regimen is compatible with letrozole-palbociclib in patients with endocrine-sensitive, hormone receptor-positive, and ERBB2 ERBB2- negative advanced breast cancer.

Of Cussac-A Llombart, Pérez-García JM, Bellet M, et Al-Palbociclib Fulvestrant, Letrozole VS-Palbociclib AS-Sensitive Endocrine for the Initial Therapy, Hormone Receptor-Positive,.

Of Cussac-A Llombart, Pérez-García JM, Bellet M, et Al-Palbociclib Fulvestrant, Letrozole VS-Palbociclib AS-Sensitive Endocrine for the Initial Therapy, Hormone Receptor-Positive,.
Of ERBB2 -Negative Advanced Breast Cancer:.
A Randomized Clinical Trial  JAMA Oncol .
 Published online October 07, 2021.
doi:10.
1001/jamaoncol.
2021.
4301  Llombart-Cussac A, Pérez-García JM, Bellet M, et al.
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor– Hormone Receptor– , ERBB2 ERBB2 -Negative Advanced Breast Cancer: A Randomized Clinical Trial.
  JAMA Oncol.
JAMA Oncol.
 Published online October 07, 2021.
doi:10.
1001/jamaoncol.
2021.
4301 

 

Leave a message here